OverviewSuggest Edit

Emergent Biosolutions is a global specialty biopharmaceutical company offering specialized products that address medical needs and emerging health threats. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. Emergent Biosolutions focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats. 

TypePublic
Founded1998
HQGaithersburg, US
Websiteemergentbiosolutions.com
Employee Ratings2.9

Latest Updates

Employees (est.) (Feb 2019)1,256
Job Openings133
Revenue (FY, 2017)$560.9 M(+15%)
Share Price (Mar 2019)$48.3 (-1%)

Key People/Management at Emergent Biosolutions

Fuad El-Hibri

Fuad El-Hibri

Executive Chairman of the Board of Directors
Daniel J. Abdun-Nabi

Daniel J. Abdun-Nabi

CEO
Robert G. Kramer

Robert G. Kramer

President and Chief Operating Officer
Richard S. Lindahl

Richard S. Lindahl

Executive Vice President, Chief Financial Officer and Treasurer
Adam R. Havey

Adam R. Havey

Executive Vice President, Business Operations
Atul Saran

Atul Saran

Executive Vice President, Corporate Development and General Counsel
Show more

Emergent Biosolutions Office Locations

Emergent Biosolutions has offices in Gaithersburg, Seattle, Lansing, Hattiesburg and in 6 other locations
Gaithersburg, US (HQ)
400 Professional Dr #400
Baltimore, US
1111 S Paca St
Baltimore, US
5901 E Lombard St
Hattiesburg, US
46 Shelby Thames Dr
Lansing, US
3500 N Martin Luther King Jr Blvd
Seattle, US
2401 4th Ave #1050
Show all (11)
Report incorrect company information

Emergent Biosolutions Financials and Metrics

Emergent Biosolutions Revenue

Emergent Biosolutions's revenue was reported to be $560.87 m in FY, 2017
USD

Market capitalization (22-Mar-2019)

2.5b

Closing stock price (22-Mar-2019)

48.3

Cash (30-Sep-2018)

339.4m
Emergent Biosolutions's current market capitalization is $2.5 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

312.7m404.5m522.8m488.8m560.9m

Revenue growth, %

21%0%

Cost of goods sold

62.1m

Gross profit

250.6m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

89.1m53.9m110.3m138.0m63.6m126.1m164.9m111.0m101.5m142.9m116.9m100.8m149.4m117.8m220.2m173.7m

Cost of goods sold

20.1m

Gross profit

69.0m

Gross profit Margin, %

77%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

179.3m280.5m312.8m271.5m178.3m

Accounts Receivable

60.6m58.8m120.8m138.5m143.7m

Inventories

14.6m65.7m76.9m74.0m142.8m

Current Assets

273.1m432.2m538.6m510.2m485.4m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

30.3m36.7m62.9m51.8m82.6m

Depreciation and Amortization

19.0m42.6m

Inventories

518.0k4.2m(11.3m)(9.0m)6.1m

Accounts Payable

(551.0k)(9.3m)4.7m(14.8m)16.1m(7.0m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

15.0m(20.2m)(15.2m)6.6m(21.5m)(7.4m)29.5m4.0m(7.0m)14.4m10.5m15.1m48.7m45.2m66.2m

Depreciation and Amortization

13.5m6.8m15.3m24.3m8.5m17.3m25.9m8.8m17.8m28.2m10.2m20.1m29.9m12.4m24.7m37.1m

Inventories

(1.2m)(4.0m)1.2m4.7m(16.5m)(19.0m)(14.4m)(11.3m)(19.7m)(16.2m)3.3m3.5m5.1m(12.4m)3.4m17.1m

Accounts Payable

(1.6m)(10.7m)(10.4m)(11.2m)1.1m2.1m1.9m385.0k11.3m(1.3m)81.0k4.2m3.0m3.6m(4.4m)(5.7m)
USDY, 2018

Financial Leverage

1.2 x
Show all financial metrics

Emergent Biosolutions Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
Adapt PharmaAugust 29, 2018$735 m
PaxVaxAugust 10, 2018$270 m
Report incorrect company information

Emergent Biosolutions Online and Social Media Presence

Embed Graph
Report incorrect company information

Emergent Biosolutions News and Updates

Emergent BioSolutions Initiates Phase 3 Clinical Study to Evaluate AV7909 for Post-Exposure Prophylaxis of Anthrax

GAITHERSBURG, Md., March 19, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase 3 trial to evaluate the lot consistency, immunogenicity, and safety of AV7909 (anthrax vaccine adsorbed with CPG 7909 adjuvant) following a two-dose schedule admini…

Emergent BioSolutions Awarded U.S. Department of State Contract to Supply Medical Countermeasures For Chemical Warfare Agents

GAITHERSBURG, Md., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has signed an indefinite-delivery, indefinite-quantity (IDIQ) contract with the U.S. Department of State to establish a long-term, reliable, and stable supply chain for medical count…

Emergent BioSolutions Reports Fourth Quarter and Full Year 2018 Financial Results

GAITHERSBURG, Md., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) reported financial results for the quarter and year ended December 31, 2018.

Emergent BioSolutions Announces Appointment of Seamus Mulligan to its Board of Directors

GAITHERSBURG, Md., Feb. 12, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the appointment of Seamus Mulligan to the company’s Board of Directors effective March 19, 2019. Mr. Mulligan was a co-founder and principal investor of Adapt Pharma Ltd. and served as its ch…

Anthrax Treatment Market Top key Players like: GSK, Elusys Therapeutics, Emergent Biosolutions and Forecast to 2025

Global Anthrax Treatment Market strives to offer significant and profound insights into the present market scenario and the emerging growth dynamics. Posted via Industry Today. Follow us on Twitter @IndustryToday

Vaccine Contract Manufacturing market by focusing on top key vendors like Diosynth, Emergent BioSolutions, Goodwin Biotechnology

Vaccine Contract Manufacturing market provides a detailed analysis of the industry and examines the factors that impact on the market’s demand, key trends and challenges faced by industry participants. The guidance provided on this website will ensure that the company implements an effective data ri…
Show more
Report incorrect company information

Emergent Biosolutions Frequently Asked Questions

  • When was Emergent Biosolutions founded?

    Emergent Biosolutions was founded in 1998.

  • Who are Emergent Biosolutions key executives?

    Emergent Biosolutions's key executives are Fuad El-Hibri, Daniel J. Abdun-Nabi and Robert G. Kramer.

  • How many employees does Emergent Biosolutions have?

    Emergent Biosolutions has 1,256 employees.

  • Who are Emergent Biosolutions competitors?

    Competitors of Emergent Biosolutions include Adverse Health, Luitpold Pharmaceuticals and ContinuumRx.

  • Where is Emergent Biosolutions headquarters?

    Emergent Biosolutions headquarters is located at 400 Professional Dr #400, Gaithersburg.

  • Where are Emergent Biosolutions offices?

    Emergent Biosolutions has offices in Gaithersburg, Seattle, Lansing, Hattiesburg and in 6 other locations.

  • How many offices does Emergent Biosolutions have?

    Emergent Biosolutions has 11 offices.